Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction

Area of Science:

• Cardiology
• Interventional Cardiology
• Heart Failure Management

Background:

• Severe ischemic left ventricular systolic dysfunction poses a significant clinical challenge.
• The comparative effectiveness of revascularization versus optimal medical therapy alone for such patients remains uncertain.

Purpose of the Study:

• To evaluate whether percutaneous coronary intervention (PCI) improves event-free survival and left ventricular function in patients with severe ischemic left ventricular systolic dysfunction compared to optimal medical therapy alone.

Main Methods:

• A randomized trial involving 700 patients with left ventricular ejection fraction ≤35% and extensive coronary artery disease.
• Patients were assigned to either PCI plus optimal medical therapy or optimal medical therapy alone.
• The primary outcome was a composite of death from any cause or hospitalization for heart failure.

Main Results:

• Over a median of 41 months, the primary outcome occurred in 37.2% of the PCI group and 38.0% of the optimal-medical-therapy group (hazard ratio, 0.99; P=0.96).
• Left ventricular ejection fraction and quality-of-life scores showed no significant long-term benefit with PCI compared to optimal medical therapy alone.

Conclusions:

• Percutaneous coronary intervention (PCI) did not reduce the incidence of death or heart failure hospitalization in patients with severe ischemic left ventricular systolic dysfunction receiving optimal medical therapy.
• Optimal medical therapy alone is a viable strategy for managing these high-risk patients.